Switzerland Extends Zurich Cannabis Pilot to 2028 After Strong Results

Switzerland's federal government has granted Zurich's legal cannabis pilot program a four-year extension through 2028, citing positive preliminary data on black market reduction and public health metrics.

The extension marks a significant policy shift for the traditionally conservative Alpine nation, which has historically maintained strict drug laws despite its harm reduction approach to drug use. Zurich's pilot, launched in 2021, allows approximately 2,100 registered participants to purchase cannabis legally from licensed pharmacies.

"The data we're seeing from Zurich suggests that regulated access can coexist with public health goals," said Andreas Gerber, spokesperson for Switzerland's Federal Office of Public Health. "We're particularly interested in the reduction of illicit market activity."

The Numbers

Preliminary findings from the pilot show measurable shifts in consumer behavior. Participants reported a 67% decrease in black market cannabis purchases since joining the program, according to data collected by the University of Zurich's research team. The pilot also tracked a modest decline in problematic use patterns among registered participants.

The program operates under strict parameters. Participants must be Zurich residents aged 18 or older with a history of cannabis use. They can purchase up to 10 grams per day from participating pharmacies, which source products from licensed Swiss cultivators. The cannabis is tested for potency and contaminants before sale.

Switzerland's approach differs markedly from commercial models in North America. There's no advertising, no storefronts with neon signs, and no branding beyond basic product information. The pilot treats cannabis as a controlled substance requiring medical-style oversight rather than a consumer product.

Regional Momentum

Zurich isn't alone. Basel and Geneva are running similar pilots with a combined 4,000 participants across Switzerland. The federal extension applies to all three programs, though each city maintains separate research protocols and purchasing limits.

The Swiss model has drawn attention from European policymakers watching Germany's recent legalization efforts with interest. While Germany moved toward a social club model in 2024, Switzerland's pharmacy-based approach offers a different template for regulated access.

"European countries are exploring multiple pathways," noted Martin Jelsma, director of the Drugs & Democracy program at the Transnational Institute. "Switzerland's pilot provides valuable data on a more medicalized approach to regulation."

What's Next

The extension through 2028 allows researchers to collect longitudinal data on long-term health outcomes, market displacement effects, and social impacts. Federal officials have indicated that positive results could inform national cannabis policy reform, though no timeline exists for broader legalization.

Switzerland's parliament has debated cannabis reform multiple times over the past decade. A 2021 proposal for nationwide regulation failed to advance, but political sentiment has shifted as pilot data accumulates. The Swiss People's Party, traditionally opposed to drug policy liberalization, has softened its stance in recent months.

For now, the pilots remain limited in scope and geography. But the extension signals growing confidence among Swiss policymakers that regulated cannabis access can achieve harm reduction goals without the social costs that legalization opponents have warned about.

The federal government will conduct a comprehensive review in 2026 to assess whether the pilots should continue beyond 2028 or inform broader policy changes. Until then, Zurich's pharmacies will continue serving as laboratories for what may become Europe's next model for cannabis regulation.

---

This article is based on original reporting by hightimes.com.